微型化儿科连续流装置:慢性绵羊模型临床前评估
Infant Jarvik 2015 是一种植入式轴流心室辅助装置(VAD),经血液相容性设计改良后,在10只Barbado绵羊(26(19-34] kg)左胸切开植入,以华法林抗凝并按可耐受最高转速运行。8只完成预定周期(2只30天、6只60天),无明显溶血,最终血浆游离血红蛋白2(1-17) mg/dL,尸检见7只陈旧性肾梗死,流量随转速升高可达3.0 L/min。
要点
- 10只绵羊中8只完成30或60天支持,6只60天者体重适度增长
- 无明显临床显著溶血,最终血浆游离血红蛋白2(1-17) mg/dL
- 7只尸检见陈旧性肾梗死,2只找到移植物涂层材料与碎裂心肌等其他栓子来源
核心结论
- Infant Jarvik 2015 VAD可在较长时间内维持功能且溶血轻微。
研究设计与样本
- 在Barbado绵羊(n=10,26(19-34] kg)经左胸切开植入VAD,华法林抗凝,目标INR高于个体基线,按可耐受最高转速管理,研究结束行完整尸检。
主要发现
- 2例早期死亡:张力性气胸(n=1)与碎裂心肌栓塞(n=1);其余8只(2只30天、6只60天方案)状态良好完成研究,6只60天者支持期间体重适度增长。
- 无明显临床显著溶血,最终血浆游离血红蛋白2(1-17) mg/dL。
- 尸检示7只绵羊陈旧性肾梗死;虽血栓栓塞可为潜在病因,但鉴于抗凝强度较轻,2只绵羊发现其他栓子来源(移植物涂层材料与碎裂心肌)。
- 流量研究显示流量随泵速变化成比例良好增加,最高达3.0 L/min。
临床怎么用
- 该临床前结果支持Infant Jarvik 2015向FDA提交研究性器械豁免申请的数据准备。
局限性
- 样本为绵羊(n=10),非人类受试者,结果外推至儿科患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Infant Jarvik 2015 is an implantable axial-flow ventricular assist device (VAD) that has undergone the major evolutionary design modifications to improve hemocompatibility. This study was conducted in anticipation of data submission to the US Food and Drug Administration to obtain Investigational Device Exemption approval. METHODS: The VAD was implanted via a left thoracotomy in Barbado sheep (n = 10, 26 (19-34] kg). Anticoagulation was maintained with coumadin, with a target international normalized ratio of greater than the individual sheep's baseline values. The VAD was managed at the highest possible speed as clinically tolerable. Complete necropsy was performed at the end of the study. RESULTS: There were 2 early mortalities: tension pneumothorax (n = 1) and shower emboli of the fragmented myocardium (n = 1). The remaining 8 sheep (2 with 30-day and 6 with 60-day protocols) completed the anticipated study duration in excellent condition, with the 6 completing 60-day sheep showing appropriate weight gain during support. There were no signs of clinically significant hemolysis, with the final plasma-free hemoglobin of 2 (1-17) mg/dL. Necropsy showed old renal infarction in 7 sheep. Although thromboembolism can be the potential etiology, given the mild anticoagulation regimen, other sources of emboli were identified in 2 sheep (graft coating material and fragmented myocardium). Flow study demonstrated favorable increase in flow (up to 3.0 L/min) in proportion to change in pump speed. CONCLUSIONS: This study has demonstrated that the Infant Jarvik 2015 VAD is capable of maintaining its functionality for an extended period of time with minimal hemolysis.
引用
- Adachi I, Burki S, Horne D, et al. The miniaturized pediatric continuous-flow device: Preclinical assessment in the chronic sheep model. J Thorac Cardiovasc Surg. 2017. PMID: 28495065. doi:10.1016/j.jtcvs.2016.12.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。